We also need to consider the age group of the three cohorts
Median ages
1: 70 (46 to 76)
2: 75 (51 to 89)
3: 73.5 (56 to 85)
As mentioned they have all failed on previous treatments with potentially compromised immune systems and elderly, and late stage lung cancer, with one patient aged 89. No offense intended but these patients are the worst case scenario for any treatment regime.
Great results in my opinion, now let's move on with combination therapy in a more resilient cohort (no prior treatments, potentially younger and still healthy immune systems)
my opinion only
Ann: Imugene Presents New PD1-Vaxx Data at the 2022 WCLC, page-54
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $331.0M | |||
| Open | High | Low | Value | Volume |
| 4.6¢ | 4.6¢ | 4.4¢ | $345.6K | 7.692M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 5792307 | 4.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 1091133 | 16 |
View Market Depth
| Last trade - 14.12pm 07/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |